Ionis Pharmaceuticals IONS Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost.
The official record: Ionis Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's effective income tax rate reconciliation nondeductible expense share based compensation cost.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's effective income tax rate reconciliation nondeductible expense share based compensation cost?
- Ionis Pharmaceuticals (IONS) reported effective income tax rate reconciliation nondeductible expense share based compensation cost of -5.1% in Q4 2025.
- What does effective income tax rate reconciliation nondeductible expense share based compensation cost mean?
- The percentage point increase in the effective tax rate caused by non-deductible share-based compensation.
- How do you interpret effective income tax rate reconciliation nondeductible expense share based compensation cost?
- An increase suggests that share-based compensation is creating a larger tax drag on the company's earnings.
- How does effective income tax rate reconciliation nondeductible expense share based compensation cost compare across companies?
- Used to compare the tax-efficiency of compensation strategies across peer companies.